ONCODNA
7.4.2021 08:51:06 CEST | Business Wire | Press release
OncoDNA, a theranostic and genomic company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce a new collaboration that will revolutionize cancer care. The two companies agreed to consolidate their core technologies to enable the production of personalized vaccines for patients who have run out of treatment options.
With the COVID-19, the field of mRNA therapeutics has been moving faster than ever before. In oncology, personalized vaccines can help fight cancer by selectively boosting the immune system. These vaccines can teach the body to recognize and eliminate tumor-specific neoantigens.
OncoDNA and myNEO will leverage their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. While OncoDNA will perform whole genome and whole transcriptome sequencing, myNEO will handle the advanced interpretation of the sequenced data and design the optimal vaccine construct for maximum clinical benefit.
The project promises to guide patients through a completely personalized journey. The eligible patients would receive tailor-made vaccines as well as personalized follow-up by monitoring circulating tumor DNA after inoculation. With its OncoFOLLOW™ liquid biopsy, OncoDNA will help monitor the patient response and the evolution of the cancer very closely using personalized next-generation sequencing method.
“OncoDNA is delighted to jump with myNEO into this ambitious project. We stand at the forefront of innovation and the challenges ahead are herculean. Together we will work towards a world where patients with a hard-to-treat disease will have the opportunity to design their personalized elixirs. It may take years before this technology becomes a reality. However, the ongoing pilot tests on patients who do not respond to any therapy are showing promising results ”, commented Jean-Pol Detiffe, Chief Strategy & Innovation Officer and Founder of OncoDNA.
“Since day 1, myNEO’s mission has been to unlock the promise of immunotherapy via deep genomic and immune profiling of tumors,” described Cedric Bogaert, co-founder and CEO of myNEO. “Currently, our technology is used by biopharma partners to design the upcoming breakthrough immuno-oncology therapies. This project takes our ambition one step further in enabling OncoDNA’s vast network of clinicians and patients to directly benefit from this deep genomic and immune profiling. As such, this project holds great potential to make individualized immunotherapies more accessible to patients.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406006220/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline and Veridas Join Forces to Fight Identity Fraud with a Global Identity Platform16.7.2026 11:21:00 CEST | Press release
Founded in Europe, now with global reach: backed by European investors and bringing bank-grade European compliance standards to markets worldwide Customer Value: A streamlined, end-to-end user experience that protects identity across the entire customer lifetime and helps customers grow revenue safely and compliantly. The Expected Result:Fourthline and Veridas are joining forces to create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US. One trusted partner for end-to-end KYC, AML, and Identity compliance. Terms of Deal: Following completion of the merger, Veridas shareholders (including BBVA) will continue as shareholders in the combination, and the transaction will be partially funded by existing Fourthline investor Finch Capital and new investors including Rabo Investments, the captive investment arm of Rabobank. Expected close is in the second half of 2026, pending c
Tax Systems Rebrands as Alphatax16.7.2026 10:00:00 CEST | Press release
New brand unveiled at Tax Tech Live 2026 as company sets out AI-powered vision to become the trusted intelligence powering modern tax Tax Systems, a global tax and accounting software provider, today announced it is rebranding as Alphatax, aligning the company with its flagship corporation tax compliance solution and marking the next stage in its evolution as an AI-first technology business. The rebrand reflects the company's ambition to redefine how tax professionals work through connected, AI-powered technology. As Alphatax, the business is bringing together compliance, data, governance and intelligence into a single platform, creating the foundations for the world’s first tax operating system: a connected environment where tax data, decisions, approvals, filings and evidence can come together. The new identity builds on the strong reputation of Alphatax, a market-leading corporation tax software trusted by tax professionals across the world. Bringing the company’s expanding portfoli
SWISSto12 Closes US$70 Million Series C to Meet Growing Multi-Orbit Demand16.7.2026 09:00:00 CEST | Press release
Swiss satellite and payload manufacturer announces close of Series C on the back of 110% CAGR since 2022 and a total of more than $500 million in contracted orders. SWISSto12, a leading enabler of the new space economy, today announced the close of its $70 million (€61 million) Series C. This news follows the award of $84.8 million (€73 million) from European Space Agency (ESA) Member States to the HummingSat ARTES partnership project, through which ESA supports SWISSto12 in the development and in-orbit validation of HummingSat. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716342732/en/ SWISSto12 will scale its manufacturing and integration capacity to meet accelerating demand from commercial and sovereign government customers. The Series C fundraise follows a period of sustained commercial growth for the company, with revenues of $140 million (€121 million) for 2025 and total contract values now exceeding $500 million
AMINA Becomes the First Regulated Bank to Integrate Leading Crypto Payments Network, Mesh16.7.2026 08:30:00 CEST | Press release
With connectivity across 300+ providers, Mesh’s verified deposit technology eliminates friction from digital asset deposits for AMINA clients AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today becomes the first regulated bank to integrate Mesh, the leading crypto payments network. The integration embeds Mesh’s verified deposit technology directly into AMINA’s online banking platform. This allows clients to verify wallet ownership, and deposit stablecoins and digital assets in a single, streamlined flow across more than 300 wallet providers. No more copying wallet addresses by hand, switching between external tools, or completing the multi-step verification the process historically required. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715917516/en/ AMINA is the first regulated bank on Mesh. Myles Harrison, Chief Product Officer at AMINA, said: “
Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 22:00:00 CEST | Press release
Researchers across Asia-Pacific gain a new option for high-quality single cell sequencing through Garvan's Evercode WT services Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Ins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom